ArticleJMIR aging2025
Association of Insulin Resistance, Sarcopenia, and Risk of Cardiovascular Disease: Findings From the China Health and Retirement Longitudinal Study.
Article in JMIR aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- The predictive value of combined assessment of estimated glucose disposal rate and non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for cardiovascular disease risk: a nationwide cohort study.Frontiers in medicine · 2026Article
- Association between glycerol triglyceride glucose-related index and cardiovascular disease in individuals with metabolic dysfunction-associated steatotic liver disease: NHANES 1999-2023.Therapeutic advances in endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) is the main cause of death in middle-aged and older people in China. The interplay between sarcopenia and insulin resistance (IR) in driving CVD risk has not been fully understood, particularly regarding sarcopenia severity and IR heterogeneity. Objective: This study aimed to investigate the relationship between IR and sarcopenia and the risk of new-onset CVD. Methods: Using data from the China Health and Retirement Longitudinal Study (CHARLS). Cox proportional hazards models were used to assess associations of sarcopenia status (nonsarcopenia, possible sarcopenia, sarcopenia, and severe sarcopenia) and 6 IR indices (triglyceride-glucose, TyG; TyG-BMI; TyG-waist circumference; TyG-waist-to-height ratio; triglyceride/high-density lipoprotein cholesterol, TG/HDL-C; and metabolic score for insulin resistance, METS-IR) with incident CVD. Additive and multiplicative interaction analyses and subgroup analyses by age and sex were performed. Receiver operating characteristic analysis was used to determine clinically relevant cutoffs. Results: In this study, during a median 9-year follow-up, we included 5514 middle- and older-aged (≥45 y) residents, of whom 550 presented with CVD incidence. Participants with possible sarcopenia and high IR exhibited 1.24-1.85-fold higher CVD risk versus nonsarcopenia and low-IR counterparts (P<.05) after adjustment for potential confounders. While TyG-BMI and TyG-waist circumference were the strongest independent predictors, formal interaction analysis revealed that the TG/HDL-C ratio and METS-IR demonstrated the most consistent synergistic effects with possible sarcopenia (relative excess risk due to interaction=0.139 and 0.074, respectively). In subgroups of different ages and sexes, the combination of IR and sarcopenia is associated with the highest risk of CVD. Receiver operating characteristic analysis provided clinically applicable cutoffs for these indices, including TG/HDL-C ≥2.09 and METS-IR ≥34.26. Conclusions: We found that IR and sarcopenia, especially early-stage sarcopenia, synergistically increase the incidence of CVD in older adults. These findings advocate for dual-targeted CVD interventions (muscle preservation and IR mitigation) in aging societies, particularly during the transitional phase of possible sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.